-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 17, AstraZeneca and Amgen announced that the US FDA has approved the listing of Tezspire (tezepelumab-ekko) for the additional maintenance treatment of children and adults with severe asthma 12 years of age and older
Thymus stromal lymphopoietin (TSLP) is a key epithelial cytokine, located at the top of multiple inflammatory cascades, and triggers an excessive immune response to airway inflammation related to severe asthma such as allergies and eosinophils
Tezepelumab is a first-in-class human monoclonal antibody that prevents immune cells from releasing pro-inflammatory cytokines by blocking TSLP, thereby preventing asthma attacks and improving asthma control
This marketing application is supported by data from a key phase III clinical study code-named NAVIGATOR, which evaluated the efficacy and safety of tezepelumab + standard therapy (SoC) vs.
At 52 weeks of treatment, compared with placebo, patients in the tezepelumab group had a statistically and clinically significant reduction in AAER
In 2020, Amgen and AstraZeneca updated the 2012 cooperation agreement on tezepelumab
There are about 2.